ArticleBiochemical and biophysical research communications2009
A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors.
Article in Biochemical and biophysical research communications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The reduced form of the antibody CH2 domain.Protein science : a publication of the Protein Society · 2021Article
- Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.Frontiers in cellular and infection microbiology · 2021Review
- Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation.Biochemical and biophysical research communications · 2017Article
- Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Frontiers in immunology · 2017Review
- Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.Frontiers in immunology · 2017Review
- Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Proteomics. Clinical applications · 2016Review
- Engineered IgG1-Fc--one fragment to bind them all.Immunological reviews · 2016Review
- Engineered Autonomous Human Variable Domains.Current pharmaceutical design · 2016Review
- The Shark Strikes Twice: Hypervariable Loop 2 of Shark IgNAR Antibody Variable Domains and Its Potential to Function as an Autonomous Paratope.Marine biotechnology (New York, N.Y.) · 2015Article
- High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.PloS one · 2015Article
- Engineered Fc based antibody domains and fragments as novel scaffolds.Biochimica et biophysica acta · 2014Review
- Creating stable stem regions for loop elongation in Fcabs - insights from combining yeast surface display, in silico loop reconstruction and molecular dynamics simulations.Biochimica et biophysica acta · 2014Article
- Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.Current drug discovery technologies · 2014Review
- N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance.Molecular pharmaceutics · 2013Article
- Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Virologica Sinica · 2013Review
- Therapeutic antibodies against cancer.Hematology/oncology clinics of North America · 2012Review
- Candidate antibody-based therapeutics against HIV-1.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2012Review
- Yeast display of engineered antibody domains.Methods in molecular biology (Clifton, N.J.) · 2012Article
- Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.PloS one · 2012Article
- Expression, purification, and characterization of engineered antibody CH2 and VH domains.Methods in molecular biology (Clifton, N.J.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Isolated immunoglobulin CH2 domains were proposed as scaffolds for selection of binders with potential effector functions. We tested the feasibility of this approach by constructing a large (size 5 x 10(10)) library where all amino acids in two loops (BC and FG) were mutated to four residues (Y, A, D, or S). Three binders were selected from this library by panning against a gp120-CD4 complex. The strongest binder, m1a1, recognized specifically a highly conserved CD4i epitope and inhibited to various extents seven out of nine HIV-1 isolates from different clades. The loop BC and the conformational state of the scaffold are critical for its binding. These results provide a proof of concept for the potential of CH2 as a scaffold for construction of libraries containing potentially useful binders. The newly identified HIV-1 inhibitors could be further improved to candidate therapeutics and/or used as research reagents for exploration of conserved gp120 structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.